CNS Tumor clinical trials at University of California Health
2 research studies open to eligible people
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
open to eligible people ages up to 18 years
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
open to eligible people ages 18 years and up
This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care.
at UC Irvine UCLA UCSF